47
Views
9
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Cyclosporin A therapy for interstitial pneumonitis associated with rheumatic disease

, , , , , , , , , , , , , & show all
Pages 305-310 | Received 29 Jun 2001, Accepted 30 Apr 2002, Published online: 02 Jan 2014

References

  • Borel JF, Kis ZL, Beveridge T. The history of the discovery and development of cyclosporine (Sandimmune). In: Merluzzi VJ, Adams J, editors. The search for anti-inflammatory drugs. Boston: Birkhausr; 1995. p. 27–63.
  • Witcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 1994;118:39–45.
  • Pacor ML, Biasi D, Lunardi C, Cortina P, Caramaschi P, Girelli D, et al. Cyclosporine in Behget's disease: results in 16 patients after 24 months of therapy. Clin Ftheumatol 1994;13:224–7.
  • Christophers E, Mrowietz U, Henneicke HH, Farber L, Wetzel D. Cyclosporine in psoriasis. The German Multicenter Study. J Am Acad Dermatol 1992;26:86–90.
  • Pei Y, Scholey JW, Katz A, Schachter R, Murphy GF, Cattran D. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kidney Dis 1994;23:528–36.
  • Mahrle G, Schultze HJ, Farbar L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32:78–88.
  • Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S. Low dose cyclosporine versus placebo in patients with rheumatoid arthritis. Lancet 1990;335:1051–5.
  • Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, et al. Effect of low-dose cyclosporin A on systemic lupus erythema-tosus disease activity. Arthritis Rheum 1994;37:551–8.
  • Ippoliti G, Miori L, Negri M, Rovati B, Lorenzutti F, Zerbinati N, et al. Cyclosporine in treatment of progressive systemic sclerosis: clinical and immunologic findings. Transplant Proc 1994;26:3117–8.
  • Gruhn WB, Diaz-Buxo JA. Cyclosporine treatment of steroid re-sistant interstitial pneumonitis associated with dermatomyositis/ polymyositis. J Ftheumatol 1987;14:1045–7.
  • Lambie PB, Quismorio FP Jr. Interstitial lung disease and cryoglo-bulinemia in polymyositis. J Ftheumatol 1991;18:468–9.
  • Pugh MT, Collins MA, Rai A, Hollinrake K, Coppock JS. A case of adult dermatomyositis treated with cyclosporin A. Br J Ftheumatol 1992;31:855–60.
  • Lueck CJ, Trend P, Swash M. Cyclosporine in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991;54:1007–8.
  • Javier A, Joaquin T, Bonifacio A, Jose LV. Successful use of cyclosporine for the treatment of aggressive pulmonary fibrosis in a patient with rheumatoid arthritis. Arthritis Rheum 1990;33:1594–6.
  • Ando S, Kobayashi S, Yamanaka K, Hashimoto H. Successful combination therapy with cyclosporine and steroid for two patients who had interstitial pneumonitis associated with polymyositis (in Japanese). Ftiumachi 1995;35:95–9.
  • Puttick MPE, Klinkhoff AV, Chalmers A, Ostrow DN. Treatment of progressive rheumatoid interstitial lung disease with cylospor-ine. J Ftheumatol 1995;22:2163–65.
  • Borg G. Subjective effort and physical activities. Scand J Rehabil Med 1978;6:108–13.
  • Kalovidouris AE. The role of cell-mediated immunity in polymyo-sitis. Curr Opin Ftheumatol 1993;20:77–9.
  • Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995;122:715–24.
  • Kanai Y, Tokano Y, Tsuda H, Hashimoto H, Hirose S. HLA-DP positive T cells in patients with polymyositis/dermatomyositis. J Ftheumatol 1993;20:77–9.
  • Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Takasaki Y, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) - relation to Thl-and Th2-derived cytokines. Clin Exp Immunol 1999;116:169–73.
  • Murashima A, Sekigawa I, Takasaki Y, Hashimoto H. Cyclo-sporine treatment of advanced interstitial pneumonitis associated with systemic sclerosis. Jpn J Ftheumatol 1999;9:95–9.
  • Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine ki-nase elevation. A poor prognostic sign. Am J Med 1986;80:329–32.
  • Saeki T, Suzuki T, Watanabe T, Saito Y, Ito S, Honma T, et al. Prognosis of interstitial pneumonitis (IP) in polymyositis (PM)/ dermatomyositis (in Japanese). Ftiumachi 1994;34:16–21.
  • Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Ftheumatol 1999;26:1527–33.
  • Ogasawara H, Murashima A, Kaneko H, Hishikawa T, Tokano Y, Sekigawa I, et al. Effect of low-dose cyclosporine treatment on interstitial pneumonitis associated with Sjögren's syndrome. Br J Ftheumatol 1998;37:348–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.